The Bottom Line: Adding to our coverage list as SGMO’s ZFN-genome editing technology enables modification of a patient’s own stem cells and potentially provides a safer approach to current therapies for hemoglobinopathies such as beta-thalassemia and sickle cell disease. the persistence of fetal hemoglobin beyond the newborn stage mitigates the severity of these hemoglobin disorders. If successful, this could eliminate the need for life-long medications and red blood cell transfusions that are currently the standard of care for these disorders.”
SGMO closed on 5/23/13 at $7.43 on a low volume day and had traded as high as $10.80 on 5/3/13. This is definitely an actionable event and I project a $0.10 to $0.20 jump for SGMO even in a DOWN and vacation weekend market on the non-dilutive CIRM funding – it might even spill over into Tuesday. The 50 day moving average is $9.28 followed by the 200 at a low of $8.10.